Skip to main content

MoneyWorks4Me

Aurobindo Pharma’s arm receives EIR from USFDA for Unit-VI at Andhra Pradesh facility

21 Nov 2026 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Apitoria Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-VI at API manufacturing facility, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh. The API manufacturing facility has been classified as Voluntary Action Indicated (VAI). The USFDA has concluded that this inspection is now closed.

Earlier, the inspection was conducted from August 24 to August 28, 2026, and concluded with three observations. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Peers
Company Name CMP
Sun Pharma. Inds. 1885.10
Dr. Reddys Labs. 1390.50
Cipla 1414.95
Lupin 2010.00
Zydus Lifesciences 1195.05
View more..